This week in therapeutics




Licensing status

Publication and contact information



Macrophage stimulating 1 receptor c-Met-related tyrosine kinase (MST1R; RON; CD136); c-Met proto-oncogene (MET; HGFR)

Mouse studies suggest inhibiting RON could help treat metastatic cancers by inducing an antitumor immune response. In an immune-competent mouse model for metastatic breast cancer, knockout of Mst1r eliminated metastasis and induced a more robust CD8+ T cell antitumor response than no knockout. ASLAN002, an inhibitor of MET and RON, decreased metastasis to the lungs of mice compared with vehicle. Next steps include combination studies with chemotherapy.
Aslan Pharmaceuticals Pte. Ltd.'s ASLAN002 (formerly BMS-777607) is in Phase I trials to treat cancer.
Eli Lilly and Co.'s narnatumab (IMC-RON8), an anti-RON mAb, is in Phase I testing to treat cancer (see RON's new role, page 1).

SciBX 6(21); doi:10.1038/scibx.2013.514
Published online May 30, 2013

Unpatented; licensing status not applicable

Eyob, H. et al. Cancer Discov.; published online April 23, 2013;
Contact: Alana L. Welm,
Huntsman Cancer Institute at The University of Utah,
Salt Lake City, Utah